NovoCure Limited (NVCR) has a negative trailing P/E of -8.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -11.30%, forward earnings yield 21.69%. PEG 0.05 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.1 | -0.34 | 4.72 | 8.10 | - |
| 2017 | -29.0 | 0.53 | 15.75 | 10.10 | - |
| 2018 | -48.4 | 33.86 | 27.39 | 12.39 | - |
| 2019 | -1,133.4 | 12.70 | 37.62 | 23.32 | - |
| 2020 | 881.7 | -2.39 | 36.65 | 35.33 | - |
| 2021 | -133.1 | 0.35 | 18.92 | 14.51 | - |
| 2022 | -83.0 | -1.45 | 17.40 | 14.27 | - |
| 2023 | -7.7 | -0.06 | 4.38 | 3.12 | - |
| 2024 | -19.1 | 0.95 | 8.92 | 5.31 | - |
| 2025 | -10.6 | 0.49 | 4.23 | 2.20 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.54 | $82.89M | $-131.85M | -159.1% |
| 2017 | $-0.70 | $177.03M | $-61.66M | -34.8% |
| 2018 | $-0.69 | $248.07M | $-63.56M | -25.6% |
| 2019 | $-0.07 | $351.32M | $-7.23M | -2.1% |
| 2020 | $0.18 | $494.37M | $19.81M | 4% |
| 2021 | $-0.56 | $535.03M | $-58.35M | -10.9% |
| 2022 | $-0.88 | $537.84M | $-92.53M | -17.2% |
| 2023 | $-1.95 | $509.34M | $-207.04M | -40.6% |
| 2024 | $-1.56 | $605.22M | $-168.63M | -27.9% |
| 2025 | $-1.22 | $655.35M | $-136.23M | -20.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.54 | $-1.91 – $-1.17 | $694.69M | $685.79M – $709.99M | 6 |
| 2027 | $-1.17 | $-1.49 – $-0.65 | $757.9M | $695.93M – $871.69M | 6 |
| 2028 | $-0.42 | $-0.50 – $-0.37 | $915.57M | $871.24M – $997.38M | 3 |
| 2029 | $2.45 | $2.30 – $2.73 | $1.52B | $1.45B – $1.66B | 1 |
| 2030 | $4.79 | $4.49 – $5.35 | $1.84B | $1.75B – $2B | 1 |
